Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities Publisher



F Asgharzadeh FERESHTEH ; M Moradibinabaj MARYAM ; S Fanoudi SAHAR ; Wcs Chishing Cho William Chi SHING ; Y Yang YUJEONG ; M Azarian MARYAM ; M Shafiee Ardestani MEHDI ; N Nasiri NASIM ; M Ramezani Farani MARZIEH ; Ys Huh Yun SUK
Source: Advanced Pharmaceutical Bulletin Published:2024

Abstract

Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field. © 2024 Elsevier B.V., All rights reserved.